Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Zai Lab’s latest 10-K means wading through hundreds of pages on oncology trial endpoints, milestone royalties, and cross-border licensing terms. Finding when executives file Form 4s before a key Phase III read-out can be equally demanding. Stock Titan’s AI-powered SEC dashboard turns that complexity into clarity.
Our platform monitors every Zai Lab quarterly earnings report 10-Q filing, Zai Lab annual report 10-K simplified, and Zai Lab 8-K material events explained the moment they hit EDGAR. Instantly see cash-runway updates, trial spend, and collaboration revenue without scrolling line-by-line. Need fast answers to “Zai Lab SEC filings explained simply” or “understanding Zai Lab SEC documents with AI”? The summary panel delivers plain-English context, key metrics, and citation links in seconds.
Stay alerted to Zai Lab insider trading Form 4 transactions. We surface Zai Lab Form 4 insider transactions real-time, flagging option exercises and open-market buys so you can assess sentiment before headlines hit. The proxy center pairs Zai Lab proxy statement executive compensation data with visual charts that benchmark R&D bonuses and equity grants against biotech peers.
- AI snapshots of pipeline milestones hidden in 10-Qs
- Side-by-side earnings trend graphs for rapid Zai Lab earnings report filing analysis
- One-click downloads of every exhibit—agreements, trial protocols, risk factors
Whether you’re gauging dilution risk, tracking Zai Lab executive stock transactions Form 4, or reviewing disclosure notes on immunology assets, Stock Titan provides the complete, continuously updated repository—decoded for actionable insight.
Zai Lab Ltd (ZLAB) insider activity: Joshua L. Smiley, President and Chief Operating Officer, reported vesting of 15,900 Restricted Share Units (RSUs) on 08/15/2025 that resulted in the acquisition of 15,900 American Depositary Shares (ADSs). A subsequent automatic sale on 08/18/2025 disposed of 6,641 ADSs at a price of $36.236 per ADS to cover taxes. After these transactions the filing reports 76,604 ADSs beneficially owned and 31,800 RSU-related derivative securities reported as beneficially owned. The RSUs vest in equal annual installments over five years beginning 08/15/2023.
Insider transactions by Zai Lab Ltd (ZLAB): Chief Legal Officer Edmondson Frazor Titus III reported acquisition and disposition of American Depositary Shares (ADSs) tied to restricted share units (RSUs). On 08/15/2025, 4,850 ADSs were acquired upon vesting of RSUs; each ADS represents ten ordinary shares. The RSUs vest in equal annual installments over five years beginning 08/17/2021. On 08/18/2025, 1,883 ADSs were sold at $36.236 per ADS to cover taxes upon vesting. Following these transactions, the reporting person beneficially owned 42,065 ADSs. The Form 4 was filed individually and signed by an attorney-in-fact.
Chen Yajing, Chief Financial Officer of Zai Lab Ltd (ZLAB), reported changes in her beneficial ownership. On 08/14/2025 she had 1,250 restricted share units vest, converting to 1,250 American Depositary Shares (ADSs). On 08/15/2025 she sold 610 ADSs at $35.267 and 828 ADSs at $35.53; the 610-share sale was to cover taxes and the 828-share sale was executed under a Rule 10b5-1 trading plan adopted March 3, 2025.
After these transactions she beneficially owns 16,720 ADSs (each ADS = 10 ordinary shares). The filing was signed by an attorney-in-fact on 08/18/2025.
Zai Lab Limited insider sale disclosure: The filing notifies a proposed sale of 1,883 American Depositary Shares (ADS) with an aggregate market value of $68,232.95, to be sold approximately on 08/18/2025 on NASDAQ. The ADS were acquired on 08/15/2025 by restricted stock vesting from the issuer and the consideration is listed as compensation.
The filer also reported a prior sale by the same person on 06/26/2025 of 5,877 ADS for $212,344.83. The notice includes the required representation that the selling person does not possess undisclosed material adverse information about the issuer.
Zai Lab Limited (ZLAB) Form 144 filing reports a proposed sale of 6,641 American Depositary Shares acquired by restricted stock vesting on 08/15/2025. The filing lists the broker as Fidelity Brokerage Services LLC and an aggregate market value of $240,645.27. The filing shows 421,725,450 shares outstanding and an approximate sale date of 08/18/2025 on NASDAQ. The filer certifies no undisclosed material adverse information and discloses no other sales in the past three months.
Zai Lab Limited (ZLAB) Form 144 notice shows a proposed sale of 610 American Depositary Shares (ADS)$21,512.75 to be sold on 08/15/2025 via Fidelity Brokerage Services on NASDAQ. The ADS were acquired on 08/14/2025 through restricted stock vesting and were paid as compensation. The filing also discloses three prior sales by Yajing Chen during the past three months totaling 16,389 ADS for gross proceeds of $524,496.72. The filer certifies no undisclosed material adverse information.
Zai Lab Limited (ZLAB) filing of Form 144 notifies the market of a proposed sale of 828 American Depositary Shares (ADS) to be executed through Fidelity Brokerage Services on 08/15/2025 on Nasdaq. The ADS were acquired on 08/14/2025 upon restricted stock vesting and are being sold as compensation. The filing shows total shares outstanding of 421,725,450 ADS and an aggregate market value for the proposed sale of $29,418.84.
The notice also lists prior sales by the same person during the past three months totaling 16,389 ADS with gross proceeds of $528,496.72, and includes the standard signer representation that no material nonpublic information is known.
Du Ying, Chairperson & CEO of Zai Lab Ltd (ZLAB), reported option exercises and open-market sales under a Rule 10b5-1 plan. The Form 4 shows acquisitions (code M) on 08/12/2025 and 08/13/2025 of 50,000 and 46,387 American Depositary Shares (ADS) equivalents at a stated price of $0.60 (reflecting stock options). The reporting person sold the same amounts on those dates under the 10b5-1 plan for weighted average prices of $34.2511 and $35.4687 respectively. Following the transactions the filing reports 536,962 ADS beneficially owned. The filing notes the stock options fully vested on 10/22/2020 and the 10b5-1 plan was adopted on 11/20/2024.
RTW Investments, LP and Roderick Wong reported shared voting and dispositive power over 55,368,760 ordinary shares of Zai Lab Limited (ZLAB), equal to 5.1% of the class. The percentage is calculated using 1,084,743,860 shares outstanding as of May 2, 2025. The shares are held directly by RTW-managed funds (the RTW Funds) and the filing states the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control. RTW Investments is a Delaware limited partnership and Dr. Wong is the Managing Partner and Chief Investment Officer; both report 0 sole voting or dispositive power and 55,368,760 shared voting and dispositive power.
Zai Lab Limited (ZLAB) Form 144 discloses planned and recent insider sales of American Depositary Shares (ADS). The notice lists a proposed sale of 46,387 ADS with an aggregate market value of $1,645,285.18 to be executed through Fidelity on NASDAQ. The filing shows the ADS to be sold were acquired by option exercise (option granted 10/22/2015; acquisition dated 08/13/2025) and the payment method is cash. The filing also itemizes sales by the same person in the prior three months totaling 284,048 ADS for approximately $9.26 million. Outstanding ADS are listed as 421,725,450, so these disclosed transactions represent a small fraction of total shares.
FAQ
What is the current stock price of Zai Lab (ZLAB)?
What is the market cap of Zai Lab (ZLAB)?
